Transition Therapeutics - Articles and news items

Phase 2/3 study of ELND005 did not meet primary efficacy endpoint

Industry news / 24 June 2015 / Victoria White

A Phase 2/3 clinical study of ELND005 in agitation and aggression in patients with Alzheimer’s disease (AD) did not meet its primary efficacy endpoint…

Lilly sells muscle strengthening drug TT701 to Transition Therapeutics

Industry news / 11 May 2015 / Victoria White

Transition Therapeutics has exclusively licensed worldwide rights to a novel small molecule drug candidate, TT701, from Eli Lilly and Company…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+